Collateral for a security interest recorded Jun 30, 2023 (Cibc Bank USA).
Term ends no later than Jan 5, 2027 · Medium confidence
20-year base term ends Jan 5, 2027
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Vertical Pharmaceuticals, LLC
Filed Jan 5, 2007 as application 11/650,227 · Granted Aug 28, 2012
Base term, 20 years from filing
Today
2007
2027
Clock starts
Jan 5, 2007
Jan 5, 2007
Ends no later than
Jan 5, 2027
Jan 5, 2027
Granted
Aug 28, 2012
Aug 28, 2012
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
30
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 5, 2007, when this application, 11/650,227, was filed | Jan 5, 2027 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Jan 5, 2027 | Medium confidence |
This family
| US 8,357,114 | In force Feb 2027 | Feb 2027 |
| US 8,202,535 | In force Oct 2030 | Oct 2030 |
| US 8,252,328 | this patent no later than Jan 2027 | no later than Jan 2027 |
| Application PCT/US2007/000527 | PCT application no patent term | no patent term |
| Application PCT/US2007/000529 | PCT application no patent term | no patent term |
| Application PCT/US2007/000528 | PCT application no patent term | no patent term |
| US 9,066,847 | In force Aug 2031 | Aug 2031 |
| US 8,252,329 | In force no later than Aug 2027 | no later than Aug 2027 |
8 of 30 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 31, 2007 Reel 19363, frame 109 | Tzannis, Stelios; Palmer, Pamela; Schreck, Thomas; Hamel, Larry; Poutiatine, Andrew I. | Acelrx Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 15, 2010 Reel 23793, frame 667 | Tzannis, Stelios; Palmer, Pamela; Schreck, Thomas; Hamel, Larry; Poutiatine, Andrew I. | Acelrx Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Apr 25, 2023 Reel 63434, frame 858 | Acelrx Pharmaceuticals, Inc. | Vertical Pharmaceuticals, LLC | Assignment of Assignor's Interest |
| Jun 30, 2023 Reel 64133, frame 94 | Vertical Pharmaceuticals, LLC | Cibc Bank USA | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2027
Term ends no later than Jan 5, 2027. No further fees fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Jan 5, 2027. We will not guess the cap.
Citations
50
later US patents cite this one
That is top 25% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.